Abstract
A series of 301 cases of male breast carcinoma has been analysed; of these, 292 have been treated at The Christie Hospital, Manchester and followed-up for a maximum of 15 years. The mean age was 63 years. The corrected survival was 52%, 38% and 36% at 5, 10 and 15 years respectively. For clinical Stage I, the 15 year survival was 61%. Since 1976, adjuvant Tamoxifen for one year has been administered to patients with operable Stage II (path) and Stage III disease following surgery and radiotherapy. Twenty-three patients so treated have a corrected survival of 55% at 5 years compared to 28% previously. Of 22 tumours assayed for oestrogen and progesterone receptors, 86% showed a positive result. For recurrent/metastatic disease, the drug Tamoxifen is recommended as the treatment of choice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Ribeiro, G. Male breast carcinoma--a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 51, 115–119 (1985). https://doi.org/10.1038/bjc.1985.16
Issue Date:
DOI: https://doi.org/10.1038/bjc.1985.16
This article is cited by
-
Outcome of non-metastatic male breast cancer: 118 patients
Medical Oncology (2012)
-
A population-based study of the impact of post-mastectomy radiation on survival for male breast cancer
Journal of Radiation Oncology (2012)
-
Papillary carcinoma of the male breast: Report of a case
Surgery Today (2011)
-
Understanding and management of male breast cancer: a critical review
Medical Oncology (2008)